Korrektur
Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma
New England Journal of Medicine · 09.04.2026 · 394 (14) · 1456-1456
DOI: 10.1056/nejmx250006 ↗Kurz gefasst
Korrektur in der Zeitschrift New England Journal of Medicine, erschienen am 09.04.2026.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
(2026). Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma. New England Journal of Medicine, 394(14), 1456-1456. https://doi.org/10.1056/nejmx250006
Vancouver
Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma. New England Journal of Medicine. 2026;394(14):1456-1456. doi:10.1056/nejmx250006
BibTeX
@article{euvimed2026,
title = {Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma},
journal = {New England Journal of Medicine},
year = {2026},
volume = {394},
number = {14},
pages = {1456--1456},
doi = {10.1056/nejmx250006}
}
EUVIMED